AbbVie Inc
ABBV: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$913.00 | Drrf | Mrwlvck |
AbbVie's Next Generation Immunology Drugs Are Offsetting the Biosimilar Pressures to Humira
Business Strategy and Outlook
AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term, we believe the firm's remaining portfolio will mitigate these losses.